Development of Alzheimer’s Disease Biomarkers: From CSF- to Blood-Based Biomarkers

In the 115 years since the discovery of Alzheimer’s disease (AD), our knowledge, diagnosis, and therapeutics have significantly improved. Biomarkers are the primary tools for clinical research, diagnostics, and therapeutic monitoring in clinical trials. They provide much insightful information, and...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Sakulrat Mankhong, Sujin Kim, Seongju Lee, Hyo-Bum Kwak, Dong-Ho Park, Kyung-Lim Joa, Ju-Hee Kang
Format: Artigo
Jezik:Inglês
Izdano: MDPI AG 2022-04-01
Serija:Biomedicines
Teme:
Alzheimer’s biomarker
cerebrospinal fluid
blood-based biomarker
clinical trial
amyloid-beta
tau
Online pristup:https://www.mdpi.com/2227-9059/10/4/850
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items